➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Moodys
Johnson and Johnson
Dow
Colorcon

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

Details for Patent: RE41920


Email this page to a colleague

« Back to Dashboard

Summary for Patent: RE41920
Title:Isobutylgaba and its derivatives for the treatment of pain
Abstract:The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
Inventor(s): Singh; Lakhbir (Cambridgeshire, GB)
Assignee: Warner-Lambert Company LLC (New York, NY)
Application Number:11/983,750
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent RE41920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE41920

PCT Information
PCT FiledJuly 16, 1997PCT Application Number:PCT/US97/12390
PCT Publication Date:January 29, 1998PCT Publication Number: WO98/03167

International Family Members for US Patent RE41920

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 241351 ⤷  Free Forever Trial
Australia 3602497 ⤷  Free Forever Trial
Australia 714980 ⤷  Free Forever Trial
Brazil 9710536 ⤷  Free Forever Trial
Canada 2255652 ⤷  Free Forever Trial
China 1094757 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Dow
Moodys
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.